Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Bipolar DisorderBipolar DepressionDepression
Interventions
DRUG

ziprasidone (Geodon)

ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.

DRUG

placebo

Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.

Trial Locations (4)

27704

Duke University, Durham

60201

Northwestern University, Chicago

02111

Tufts University, Boston

02139

Cambridge Health Alliance, Cambridge

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Tufts Medical Center

OTHER